16 May 2026VideosBiotechMichael Shuster, Goodwin Law | Guy Birkenmeier, New England Biolabs | Michael Penn, BlueRock Therapeutics | Ben Doranz, Integral Molecular
WATCH: Overcoming obstacles in antibody patent protection
As antibodies cement their status as a major therapeutic class, securing robust IP protection has grown increasingly difficult. With heightened scrutiny on enablement and written description requirements, this panel unpacks strategies for building resilient antibody portfolios in a challenging global landscape.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 November 2026 A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.
16 November 2026 The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
13 November 2026 Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.